Fyarro (Sirolimus Protein-Bound) Patent Expiration, LOE Window & CMS Spending

Fyarro (Sirolimus Protein-Bound) by Aadi Bioscience: FDA Orange Book LOE 2040-10-28, 4 AB generics, $1.5M 2024 CMS Part D & Medicaid spend, and 4 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAadi Bioscience
FDA Application & PathwayN213312 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2040-10-28
Orange Book Patents (*PED Extensions)7 patents (0 *PED)
Active AB-Rated Generic Competitors4
2024 CMS Total Public Spend$1.5M
2024 Medicare Part D Spend$0
2024 Medicaid Spend$1.5M
Reported Wholesale Price Change (CA SB 17)4 WAC filings (max 24.7% 2-yr change)